Literature DB >> 7357805

Dynamics and kinetics of ophthalmic timolol.

M B Affrime, D T Lowenthal, J A Tobert, J Shirk, B Eidelson, T Cook, G Onesti.   

Abstract

Timolol is a beta adrenergic antagonist in 0.25% or 0.5% eyedrop solution for glaucoma. In a double-blind crossover study in healthy males we measured systemic beta blockade, intraocular pressure, and timolol kinetics after the first and ninth 12-hourly dose of a 0.5% ophthalmic solution. Timolol ophthalmic and placebo were each given as 2 drops to each eye with precautions to prevent the normal loss of drug in tears and overflow (high dose) and as 1 drop to each eye with no special precautions (standard therapeutic dose). Exercise tachycardia, measured at 70 and 255 min after administration of drug, was lower at both levels. Postexercise 1-sec forced expiratory volume (FEV1) was not affected. Intraocular pressure measured at 3 and 8 hr after drug was lower at both dose levels. Timolol was consistently present in urine but was not detectable in most plasma samples. Dynamic effects were not greater after the ninth than after the first dose, and the urinary excretion data provided no evidence of drug cumulation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357805     DOI: 10.1038/clpt.1980.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Topical timolol and serum lipoproteins.

Authors:  J West; S Longstaff
Journal:  Br J Ophthalmol       Date:  1990-11       Impact factor: 4.638

Review 2.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

Review 3.  Systemic adverse effects of topical ophthalmic agents. Implications for older patients.

Authors:  J P Diamond
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 3.923

4.  Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol.

Authors:  M Nakashima; T Uematsu; Y Takiguchi; H Hashimoto; I Watanabe; S Morioka; T Hibino
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Current concepts of pharmacotherapy in hypertension--ophthalmically administered beta blockers and their cardiopulmonary effects.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

6.  Association between Ophthalmic Timolol and Hospitalisation for Bradycardia.

Authors:  Nicole L Pratt; Emmae N Ramsay; Lisa M Kalisch Ellett; Tuan A Nguyen; Elizabeth E Roughead
Journal:  J Ophthalmol       Date:  2015-03-22       Impact factor: 1.909

7.  From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient.

Authors:  Muhammad Asim Rana; Ahmed Fouad Mady; Basheer Abdel Rehman; Abdulrahman Alharthy; Basim Huwait; Asim Riaz; Waleed Tharwat Aletreby
Journal:  Case Rep Crit Care       Date:  2015-08-06

8.  Ophthalmic Timolol and Hospitalization for Symptomatic Bradycardia and Syncope: A Case Series.

Authors:  Syed A Abbas; Syeda M Hamadani; Umair Ahmad; Aditi Desai; Karishma Kitchloo
Journal:  Cureus       Date:  2020-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.